Literature DB >> 26855027

Design and Fabrication of Multifunctional Sericin Nanoparticles for Tumor Targeting and pH-Responsive Subcellular Delivery of Cancer Chemotherapy Drugs.

Lei Huang1, Kaixiong Tao1, Jia Liu1, Chao Qi1, Luming Xu1, Panpan Chang1, Jinbo Gao1, Xiaoming Shuai1, Guobin Wang1, Zheng Wang1, Lin Wang1.   

Abstract

The severe cytotoxicity of cancer chemotherapy drugs limits their clinical applications. Various protein-based nanoparticles with good biocompatibility have been developed for chemotherapy drug delivery in hope of reducing drugs' side effects. Sericin, a natural protein from silk, has no immunogenicity and possesses diverse bioactivities that have prompted sericin's application studies. However, the potential of sericin as a multifunctional nanoscale vehicle for cancer therapy have not been fully explored. Here we report the successful fabrication and characterization of folate-conjugated sericin nanoparticles with cancer-targeting capability for pH-responsive release of doxorubicin (these nanoparticles are termed "FA-SND"). DOX is covalently linked to sericin through pH-sensitive hydrazone bonds that render a pH-triggered release property. The hydrophobicity of DOX and the hydrophilicity of sericin promote the self-assembly of sericin-DOX (SND) nanoconjugates. Folate (FA) is then covalently grafted to SND nanoconjugates as a binding unit for actively targeting cancer cells that overexpress folate receptors. Our characterization study shows that FA-SND nanoparticles exhibit negative surface charges that would reduce nonspecific clearance by circulation. These nanoparticles possess good cytotoxicity and hemocompatibiliy. Acidic environment (pH 5.0) triggers effective DOX release from FA-SND, 5-fold higher than does a neutral condition (pH 7.4). Further, FA-SND nanoparticles specifically target folate-receptor-rich KB cells, and endocytosed into lysosomes, an acidic organelle. The acidic microenvironment of lysosomes promotes a rapid release of DOX to nuclei, producing cancer specific chemo-cytotoxicity. Thus, FA-mediated cancer targeting and lysosomal-acidity promoting DOX release, two sequentially-occurring cellular events triggered by the designed components of FA-SND, form the basis for FA-SND to achieve its localized and intracellular chemo-cytotoxicity. Together, this study suggests that these FA-SND nanoparticles may be a potentially effective carrier particularly useful for delivering hydrophobic chemotherapeutic agents for treating cancers with high-level expression of folate receptors.

Entities:  

Keywords:  doxorubicin; folate; nanoparticles; pH sensitivity; sericin

Mesh:

Substances:

Year:  2016        PMID: 26855027     DOI: 10.1021/acsami.5b11617

Source DB:  PubMed          Journal:  ACS Appl Mater Interfaces        ISSN: 1944-8244            Impact factor:   9.229


  11 in total

1.  [Sericin regulates proliferation of human gastric cancer MKN45 cells through autophagic pathway].

Authors:  Wei-Hong Guo; Zhao-Yu Chen; Hao Chen; Tian Lin; Ming-Li Zhao; Hao Liu; Jiang Yu; Yan-Feng Hu; Guo-Xin Li
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-02-20

2.  Fabrication and characterization of a novel self-assembling micelle based on chitosan cross-linked pectin-doxorubicin conjugates macromolecular pro-drug for targeted cancer therapy.

Authors:  Zhi-Ping Li; Ming-Chao Jiang; Bo Chen; Pei Gao; Sa Yang; Yu-Feng Liu; Peng-Ju Ye; Dong-Xiu He; Hong-Lin Huang; Cui-Yun Yu
Journal:  RSC Adv       Date:  2018-03-28       Impact factor: 4.036

3.  In situ protein-templated porous protein-hydroxylapatite nanocomposite microspheres for pH-dependent sustained anticancer drug release.

Authors:  Yajun Shuai; Shuxu Yang; Chenlin Li; Liangjun Zhu; Chuanbin Mao; Mingying Yang
Journal:  J Mater Chem B       Date:  2017-05-12       Impact factor: 6.331

4.  Polyphenols-Loaded Sericin Self-Assembling Nanoparticles: A Slow-Release for Regeneration by Tissue-Resident Mesenchymal Stem/Stromal Cells.

Authors:  Giulia Orlandi; Elia Bari; Laura Catenacci; Milena Sorrenti; Lorena Segale; Silvio Faragò; Marzio Sorlini; Carla Renata Arciola; Maria Luisa Torre; Sara Perteghella
Journal:  Pharmaceutics       Date:  2020-04-21       Impact factor: 6.321

Review 5.  Sericin based nanoformulations: a comprehensive review on molecular mechanisms of interaction with organisms to biological applications.

Authors:  Gitishree Das; Han-Seung Shin; Estefânia V Ramos Campos; Leonardo Fernandes Fraceto; Maria Del Pilar Rodriguez-Torres; Kelli Cristina Freitas Mariano; Daniele Ribeiro de Araujo; Fabián Fernández-Luqueño; Renato Grillo; Jayanta Kumar Patra
Journal:  J Nanobiotechnology       Date:  2021-01-22       Impact factor: 10.435

Review 6.  Protein nanoparticles directed cancer imaging and therapy.

Authors:  Yao Miao; Tao Yang; Shuxu Yang; Mingying Yang; Chuanbin Mao
Journal:  Nano Converg       Date:  2022-01-08

7.  In Vitro Interaction of Doxorubicin-Loaded Silk Sericin Nanocarriers with MCF-7 Breast Cancer Cells Leads to DNA Damage.

Authors:  Ionuț-Cristian Radu; Cătălin Zaharia; Ariana Hudiță; Eugenia Tanasă; Octav Ginghină; Minodora Marin; Bianca Gălățeanu; Marieta Costache
Journal:  Polymers (Basel)       Date:  2021-06-22       Impact factor: 4.329

8.  Sericin nanomicelles with enhanced cellular uptake and pH-triggered release of doxorubicin reverse cancer drug resistance.

Authors:  Weihong Guo; Lizhi Deng; Jiang Yu; Zhaoyu Chen; Yanghee Woo; Hao Liu; Tuanjie Li; Tian Lin; Hao Chen; Mingli Zhao; Liming Zhang; Guoxin Li; Yanfeng Hu
Journal:  Drug Deliv       Date:  2018-11       Impact factor: 6.419

Review 9.  Membrane Trafficking and Subcellular Drug Targeting Pathways.

Authors:  Ajay Kumar; Anas Ahmad; Akshay Vyawahare; Rehan Khan
Journal:  Front Pharmacol       Date:  2020-05-27       Impact factor: 5.810

Review 10.  An Up-to-Date Review of Natural Nanoparticles for Cancer Management.

Authors:  Daniel Ion; Adelina-Gabriela Niculescu; Dan Nicolae Păduraru; Octavian Andronic; Florentina Mușat; Alexandru Mihai Grumezescu; Alexandra Bolocan
Journal:  Pharmaceutics       Date:  2021-12-22       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.